Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion official investor newsroom · Indexed industry source record · Source published: Wed Nov 18 2026 09:59:32 GMT+0000 (Coordinated Universal Time) · Indexed here: Wed Nov 18 2026 10:08:16 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis November 18, 2026 at 4:59 AM EST PDF Version REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.